TagSNP analyses of the PON gene cluster: Effects on PON1 activity, LDL oxidative susceptibility, and vascular disease

Journal of Lipid Research

Volumn 47, Issue 5, 2006, Pages 1014-1024

  Carlson, Christopher S ^a   Heagerty, Patrick J ^b   Hatsukami, Thomas S ^e   Richter, Rebecca J ^c   Ranchalis, Jane ^c   Lewis, Julieann ^c   Bacus, Tamara J ^c   McKinstry, Laura A ^c   Schellenberg, Gerard D ^b   Rieder, Mark ^b   Nickerson, Deborah ^b   Furlong, Clement E ^b,c   Chait, Alan ^d   Jarvik, Gail P ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Department of Biostatistics ^*

^c Division of Medical Genetics   (United States)

^d Division of Metabolism Endocrinology and Nutrition   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carotid artery disease; Genotype; Haplotype; LDL; Oxidation; Paraoxonase; Tagging single nucleotide polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; PHENYLACETIC ACID;

ADULT; AGED; ARTICLE; CAROTID ARTERY DISEASE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENE CLUSTER; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CAROTID STENOSIS; ESTERASES; GENETIC TECHNIQUES; HAPLOTYPES; HOMOCYSTEINE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33646858990     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500517-JLR200     Document Type: Article

References (83)

1. Ayub, A., M. I. Mackness, S. Arrol, B. Mackness, J. Patel, and P. N. Durrington. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19: 330-335.
2. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441-2447.
3. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. 2003a. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465-1471.
4. Mackness, B., P. N. Durrington, B. Abuashia, A. J. Boulton, and M. I. Mackness. 2000. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. (Lond.). 98: 355-363.
5. Mackness, M. I., B. Mackness, and P. N. Durrington. 2002. Paraoxonase and coronary heart disease. Atheroscler. 3 (Suppl.): 49-55.
6. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
7. Tward, A., Y. R. Xia, X. P. Wang, Y. S. Shi, C. Park, L. W. Castellani, A. J. Lusis, and D. M. Shih. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106: 484-490.
8. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129-135.
9. Mackness, M. I., D. Bhatnagar, P. N. Durrington, H. Prais, B. Haynes, J. Morgan, and L. Borthwick. 1994. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur. J. Clin. Nutr. 48: 859-865.
10. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
11. Graham, A., D. G. Hassall, S. Rafique, and J. S. Owen. 1997. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135: 193-204.
12. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26: 892-904.
13. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
14. Ruiz, J., H. Blanche, R. W. James, M. C. Garin, C. Vaisse, G. Charpentier, N. Cohen, A. Morabia, P. Passa, and P. Froguel. 1995. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346: 869-872.
15. Serrato,M., and A. J.Marian. 1995. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96: 3005-3008.
16. Pfohl, M., M. Koch, M. D. Enderle, R. Kuhn, J. Fullhase, K. R. Karsch, and H. U. Haring. 1999. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 48: 623-627.
17. Heijmans, B., R. G. Westendorp, A. M. Lagaay, D. L. Knook, C. Kluft, and P. E. Slagboom. 2000. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis. 149: 91-97.
18. Antikainen, M., S. Murtomaki, M. Syvanne, R. Pahlman, E. Tahvanainen, M. Jauhiainen, M. H. Frick, and C. Ehnholm. 1996. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98: 833-835.
19. Rice, G. I., N. Ossei-Gerning, M. H. Stickland, and P. J. Grant. 1997. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron. Artery Dis. 8: 677-682.
20. Herrmann, S. M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J. M. Bard, and F. Cambien. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126: 299-303.
21. Suehiro, T., Y. Nakauchi, M. Yamamoto, K. Arii, H. Itoh, N. Hamashige, and K. Hashimoto. 1996. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57: 69-73.
22. Schmidt, H., R. Schmidt, K. Niederkorn, A. Gradert, M. Schumacher, N. Watzinger, H. P. Hartung, and G. M. Kostner. 1998. Paraoxonase PON1 polymorphism leu-met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke. 29: 2043-2048.
23. Sanghera, D. K., N. Saha, C. E. Aston, and M. I. Kamboh. 1997. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17: 1067-1073.
24. Cascorbi, I., M. Laule, P. M. Mrozikiewicz, A. Mrozikiewicz, C. Andel, G. Baumann, I. Roots, and K. Stangl. 1999. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics. 9: 755-761.
25. Sanghera, D. K., N. Saha, and M. I. Kamboh. 1998b. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136: 217-223.
26. Lawlor, D. A., I. N. Day, T. R. Gaunt, L. J. Hinks, P. J. Briggs, M. Kiessling, N. Timpson, G. D. Smith, and S. Ebrahim. 2004. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet. 5: 17.
27. Wheeler, J. G., B. D. Keavney, H. Watkins, R. Collins, and J. Danesh. 2004. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 363: 689-695.
28. Lohmueller, K. E., C. L. Pearce, M. Pike, E. S. Lander, and J. N. Hirschhorn. 2003. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33: 177-182.
29. Chen, Q., S. E. Reis, C. M. Kammerer, D. M. McNamara, R. Holubkov, B. L. Sharaf, G. Sopko, D. F. Pauly, C. N. Merz, and M. I. Kamboh. 2003. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet. 72: 13-22.
30. Voetsch, B., K. S. Benke, B. P. Damasceno, L. H. Siqueira, and J. Loscalzo. 2002. Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke. 33: 1459-1464.
31. Voetsch, B., K. S. Benke, C. I. Panhuysen, B. P. Damasceno, and J. Loscalzo. 2004. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch. Neurol. 61: 351-356.
32. Ueno, T., E. Shimazaki, T. Matsumoto, H. Watanabe, A. Tsunemi, Y. Takahashi, M. Mori, R. Hamano, T. Fujioka, M. Soma, et al. 2003. Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Med. Sci. Monit. 9: CR208-CR212.
33. Schmidt, R., H. Schmidt, F. Fazekas, P. Kapeller, G. Roob, A. Lechner, G. M. Kostner, and H. P. Hartung. 2000. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the austrian stroke prevention study. Arterioscler. Thromb. Vasc. Biol. 20: 1811-1816.
34. Markus, H., Z. Kapozsta, R. Ditrich, C. Wolfe, N. Ali, J. Powell, M. Mendell, and M. Cullinane. 2001. Increased common carotid intima-media thickness in UK African Caribbeans and its relation to chronic inflammation and vascular candidate gene polymorphisms. Stroke. 32: 2465-2471.
35. Topic, E., A. M. Timundic, M. Ttefanovic, V. Demarin, V. Vukovic, A. Lovrencic-Huzjan, and I. Zuntar. 2001. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin. Chem. Lab. Med. 39: 346-350.
36. Reddy, S. T., D. J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D. M. Shih, A. J. Lusis, M. Navab, and A. M. Fogelman. 2001. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21: 542-547.
37. Ng, C. J., D. J. Wadleigh, A. Gangopadhyay, S. Hama, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276: 44444-44449.
38. Rosenblat, M., D. Draganov, C. E. Watson, C. L. Bisgaier, B. N. La Du, and M. Aviram. 2003. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 468-474.
39. Pan, J. P., S. T. Lai, S. C. Chiang, S. C. Chou, and A. N. Chiang. 2002. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei). 65: 415-421.
40. Martinelli, N., D. Girelli, O. Olivieri, C. Stranieri, E. Trabetti, F. Pizzolo, S. Friso, I. Tenuti, S. Cheng, M. A. Grow, et al. 2004. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur. J. Clin. Invest. 34: 14-20.
41. Rosenblat, M., T. Hayek, K. Hussein, and M. Aviram. 2004. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler. Thromb. Vasc. Biol. 24: 175-180.
42. Rosenblat, M., J. Vaya, D. Shih, and M. Aviram. 2005. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis. 179: 69-77.
43. Jakubowski, H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275: 3957-3962.
44. Jakubowski, H. 1999. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13: 2277-2283.
45. Selhub, J., P. F. Jacques, A. G. Bostom, R. B. D'Agostino, P. W. Wilson, A. J. Belanger, D. H. O'Leary, P. A. Wolf, E. J. Schaefer, and I. H. Rosenberg. 1995. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332: 286-291.
46. Bostom, A. G., and J. D. Easton. 1992. Serum lipoprotein (a) as a risk factor for extracranial carotid artery atherosclerosis [letter] [see comments]. Mayo Clin. Proc. 67: 303-304.
47. Christen, W. G., U. A. Ajani, R. J. Glynn, and C. H. Hennekens. 2000. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch. Intern. Med. 160: 422-434.
48. Clarke, R., L. Daly, K. Robinson, E. Naughten, S. Cahalane, B. Fowler, and I. Graham. 1991. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324: 1149-1155.
49. Boers, G. H., A. G. Smals, F. J. Trijbels, B. Fowler, J. A. Bakkeren, H. C. Schoonderwaldt, W. J. Kleijer, and P. W. Kloppenborg. 1985. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N. Engl. J. Med. 313: 709-715.
50. Perry, I. J., H. Refsum, R. W. Morris, S. B. Ebrahim, P. M. Ueland, and A. G. Shaper. 1995. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346: 1395-1398.
51. Dudman, N. P., D. E. Wilcken, J. Wang, J. F. Lynch, D. Macey, and P. Lundberg. 1994. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler. Thromb. Vasc. Biol. 13: 1253-1260.
52. Hamon, S. C., J. H. Stengard, A. G. Clark, V. Salomaa, E. Boerwinkle, and C. F. Sing. 2004. Evidence for non-additive influence of single nucleotide polymorphisms within the apolipoprotein E gene. Ann. Hum. Genet. 68: 521-535.
53. Stengard, J. H., A. G. Clark, K. M. Weiss, S. Kardia, D. A. Nickerson, V. Salomaa, C. Ehnholm, E. Boerwinkle, and C. F. Sing. 2002. Contributions of 18 additional DNAsequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism. Am. J. Hum. Genet. 71: 501-517.
54. Wootton, P. T., F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud. 2005. Tagging SNP haplotype analysis of the secretory PLA2-IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum. Mol. Genet. 15: 355-361.
55. Hendrickson, A., L. A. McKinstry, J. K. Lewis, J. Lum, A. Louie, G. D. Schellenberg, T. S. Hatsukami, A. Chait, and G. P. Jarvik. 2005. Ex vivo measures of LDL oxidative susceptibility predict carotid artery disease. Atherosclerosis. 179: 147-153.
56. Pritchard, J. K., M. Stephens, and P. Donnelly. 2000. Inference of population structure using multilocus genotype data. Genetics. 155: 945-959.
57. Fan, J. B., A. Oliphant, R. Shen, B. G. Kermani, F. Garcia, K. L. Gunderson, M. Hansen, F. Steemers, S. L. Butler, P. Deloukas, et al. 2003. Highly parallel SNP genotyping. Cold Spring Harb. Symp. Quant. Biol. 68: 69-78.
58. Oliphant, A., D. L. Barker, J. R. Stuelpnagel, and M. S. Chee. 2002. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques. 56-58 (Suppl.): 60-61.
59. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
60. Humbert, R.,D. A. Adler, C.M.Disteche, C. Hassett, C. J.Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
61. Brophy, V. H., M. D. Hastings, J. B. Clendenning, R. Richter, G. P. Jarvik, and C. E. Furlong. 2001a. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77-84.
62. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001b. Promoter polymorphism effects on paraoxonase (PON1) expression. Am. J. Hum. Genet. 68: 1428-1436.
63. Furlong, C. E., R. J. Richter, S. L. Seidel, L. G. Costa, and A. G. Motulsky. 1989. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyifos and parathion by plasma paraoxonase/ arylesterase. Anal. Biochem. 180: 242-247.
64. Davies, H., R. J. Richter, M. Keifer, C. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat. Genet. 14: 334-336.
65. Richter, R. J., and C. E. Furlong. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9: 745-753.
66. Furlong, C. E., N. Holland, R. J. Richter, A. Bradman, A. Ho, and B. Eskenazi. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics. 16: 183-190.
67. Esterbauer, H., G. Striegl, H. Puhl, and M. Rotheneder. 1989. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6: 67-75.
68. Crawford, R. S., E. A. Kirk, M. E. Rosenfeld, R. C. LeBoeuf, and A. Chait. 1998. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18: 1506-1513.
69. Stephens, M., N. J. Smith, and P. Donnelly. 2001. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989.
70. Lake, S. L., H. Lyon, K. Tantisira, E. K. Silverman, S. T. Weiss, N. M. Laird, and D. J. Schaid. 2003. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum. Hered. 55: 56-65.
71. Carlson, C. S., M. A. Eberle, M. J. Rieder, Q. Yi, L. Kruglyak, and D. A. Nickerson. 2004. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74: 106-120.
72. Chen, J., W. Chan, S. Wallenstein, G. Berkowitz, and J. G. Wetmur. 2005. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol. Biomarkers Prev. 14: 731-734.
73. Jarvik, G. P., R. Jampsa, R. J. Richter, C. S. Carlson, M. J. Rieder, D. A. Nickerson, and C. E. Furlong. 2003b. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 13: 291-295.
74. Teiber, J. F., D. I. Draganov, and B. N. La Du. 2004. Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J. Lipid Res. 45: 2260-2268.
75. Draganov, D. I., J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46: 1239-1247.
76. Sardo, M. A., S. Campo, M. Bonaiuto, A. Bonaiuto, C. Saitta, G. Trimarchi, M. Castaldo, A. Bitto, M. Cinquegrani, and A. Saitta. 2005. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr. Med. Res. Opin. 21: 777-784.
77. Marathe, G. K., G. A. Zimmerman, and T. M. McIntyre. 2003. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278: 3937-3947.
78. Mackness, B., D. Hine, Y. Liu, M. Mastorikou, and M. Mackness. 2004. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318: 680-683.
79. Connelly, P.W., D. Draganov, and G. F. Maguire. 2005. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic. Biol. Med. 38: 164-174.
80. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527-17535.
81. Oda, M. N., J. K. Bielicki, T. T. Ho, T. Berger, E.M. Rubin, and T. M. Forte. 2002. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290: 921-927.
82. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du. 1998a. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
83. Bub, A., S. W. Barth, B. Watzl, K. Briviba, and G. Rechkemmer. 2005. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. Br. J. Nutr. 93: 291-297.